tiprankstipranks
Advertisement
Advertisement

DE:8F8 Stock Latest News

SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
Company AnnouncementsSynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
17h ago
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
PremiumCompany Announcements
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
14d ago
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
PremiumCompany Announcements
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
1M ago
SynAct preclinical data point to osteoarthritis potential for resomelagon
PremiumCompany Announcements
SynAct preclinical data point to osteoarthritis potential for resomelagon
1M ago
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
PremiumCompany Announcements
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
2M ago
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
PremiumCompany AnnouncementsSynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
2M ago
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
Premium
Company Announcements
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
2M ago
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
Premium
Company Announcements
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
2M ago
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
PremiumCompany Announcements
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
2M ago
8F8
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
PremiumCompany Announcements
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
2M ago
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
PremiumCompany Announcements
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
3M ago
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
PremiumCompany Announcements
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
3M ago
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
PremiumCompany AnnouncementsSynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
3M ago
SynAct Pharma convenes AGM and opts to retain earnings
Premium
Company Announcements
SynAct Pharma convenes AGM and opts to retain earnings
3M ago
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
Premium
Company Announcements
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
4M ago
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
PremiumCompany Announcements
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
4M ago
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
PremiumCompany Announcements
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
4M ago
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
PremiumCompany Announcements
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
4M ago
SynAct Pharma Raises Share Capital Through Directed Issue
PremiumCompany Announcements
SynAct Pharma Raises Share Capital Through Directed Issue
5M ago
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
PremiumCompany AnnouncementsSynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
5M ago
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
Premium
Company Announcements
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
5M ago
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
Premium
Company Announcements
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >